| Literature DB >> 24559218 |
Anita Stern1, Nicholas Mitsakakis, Mike Paulden, Shabbir Alibhai, Josephine Wong, George Tomlinson, Ann-Sylvia Brooker, Murray Krahn, Merrick Zwarenstein.
Abstract
BACKGROUND: The study was conducted to determine the clinical and cost effectiveness of enhanced multi-disciplinary teams (EMDTs) vs. 'usual care' for the treatment of pressure ulcers in long term care (LTC) facilities in Ontario, CanadaEntities:
Mesh:
Year: 2014 PMID: 24559218 PMCID: PMC4104322 DOI: 10.1186/1472-6963-14-83
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Study design
| - | - | - | - | - | - | - | c | c | c | c | c | c | ||||||
| - | - | - | - | - | - | c | c | c | c | c | ||||||||
| c | c | c | c | c | c | c | c | c | c | c | c | |||||||
| c | c | c | c | c | c | c | c | c | c | c | ||||||||
| c | c | c | c | c | c | c | c | c | c | |||||||||
| c | c | c | c | c | c | c | c | c | ||||||||||
| c | c | c | c | c | c | c | c | |||||||||||
| c | c | c | c | c | c | c | ||||||||||||
| c | c | c | c | c | c | |||||||||||||
| c | c | c | c | c | ||||||||||||||
| c | c | c | c | |||||||||||||||
| c | c | c | ||||||||||||||||
c = Control; P1 = Intervention- Phase 1 (onsite one day/week); P2 = Intervention Phase 2 (primarily remote bi-weekly).
Figure 1Referral rubric.
PU prevalence
| 9.9 | 4.4 | 6.2 | 6.8 | 4.4 | |
| 10.2 | 5.9 | 2.5 | 3.5 | 2.0 | |
| 5.9 | 3.3 | 9.2 | 9.2 | 8.3 | |
| 7.0 | 4.4 | 1.0 | 3.9 | 0** | |
| 8.4 | 5.6 | 2.5 | 2.5 | 0 | |
| 6.3 | 3.8 | 2.9 | 3.8 | 0.8 | |
| 7.9 | 2.4 | 2.4 | 5.7 | 3.3 | |
| 6.8 | 0.6 | 0.6 | 5.7 | 4.4 | |
| 12.3 | 2.5 | 6.0 | 6.0 | 4.3 | |
| 6.7 | 1.9 | 3.8 | 3.8 | 4.4 | |
| 9.5 | 6.3 | 3.1 | 4.4 | 3.1 | |
| 6.8 | 3.7 | 2.1 | 2.1* | 1.6 | |
*7residents excluded from bedside audit as requested by Director of Care.
**Director of Care stopped referring residents with PUs to the study APN during phase 2 of the Intervention.
Figure 2Facility recruitment.
Figure 3Resident (wound) recruitment.
Participant characteristics
| 81 (12) | 83 (12) | |
| 43 (64.2%) | 65 (69.1%) | |
| | | |
| Alzheimer's/Dementia | 38 (56.7%) | 62 (66.0%) |
| Diabetes | 22 (32.8%) | 36 (38.3%) |
| Stroke/TIA | 20 (29.9%) | 29 (30.9%) |
| Diabetes with end organ damage | 10 (14.9%) | 22 (23.4%) |
| Paraplegia/Hemiplegia | 11 (16.4%) | 15 (16.0%) |
| Any solid tumour | 6 (9.0%) | 16 (17.0%) |
| COPD | 10 (14.9%) | 7 (7.4%) |
| Congestive Heart Failure | 4 (6.0%) | 11 (11.7%) |
| Peripheral Vascular Disease | 5 (7.5%) | 6 (6.4%) |
| Myocardial Infarction | 3 (4.5%) | 6 (6.4%) |
| Moderate or severe renal disease | 1 (1.5%) | 4 (4.3%) |
| Charlson Co-morbidity Index | 3 (2) | 3 (2) |
| | | |
| Hypertension | 37 (55.2%) | 55 (58.5%) |
| Osteoarthritis | 36 (53.7%) | 42 (44.7%) |
| Osteoporosis | 23 (34.3%) | 33 (35.1%%) |
| Coronary Artery Disease | 15 (22.4%) | 18 (19.1%) |
| Parkinson's disease | 7 (10.4%%) | 9 (9.6%) |
| Contractures | 5 (7.5%) | 6 (6.4%%) |
| Spasticity | 4 (6.0%) | 5 (5.3%) |
| | | |
| Incontinence (urine) | 66 (98.5%) | 91 (96.8%) |
| Incontinence (stool) | 58 (86.6%) | 79 (84.0%) |
| Bedbound | 49 (81.7%%) | 71 (87.7%) |
| Mental Status (Not alert/not oriented) | 52 (77.6%) | 78 (83.0%) |
| Nutritional supplement | 55 (82.1%) | 80 (85.1%) |
| Tube Feed | 5 (7.5%) | 7 (7.4%) |
| Body Mass Index | 25 (8) | 24 (6) |
*42 participants crossed study phases, extending from control to intervention i.e. double counted.
Primary analysis – healing rate
| | | ||||
|---|---|---|---|---|---|
| Random effect for intercept and slope, common treatment effect, | -0.116 | 0.0055 | 1.006 | 0.985-1.027 | 0.605 |
| Random effect for intercept and slope, common treatment effect* | -0.114 | 0.0062 | 1.006 | 0.985-1.027 | 0.539 |
| Random effect for intercept slope, and treatment effect* | -0.122 | 0.0171 | 1.020 | 0.993-1.042 | 0.161 |
| Random effect for intercept and slope, common treatment effect, control for stage at diagnosis | -0.115 | 0.0053 | 1.006 | 0.985-1.026 | 0.615 |
| | | | | | |
| Stage II: Random effect for intercept and slope, common treatment effect | -0.116 | -0.040 | 0.968 | 0.882-1.062 | 0.079 |
| Stage III: Random effect for intercept and slope, common treatment effect | -0.126 | 0.005 | 1.005 | 0.958-1.055 | 0.828 |
| Stage IV: Random effect for intercept and slope, common treatment effect | -0.125 | 0.050 | 1.050 | 1.014-1.088 | 0.006 |
| Unstageable: Random effect for intercept and slope, common treatment effect | -0.158 | 0.013 | 1.013 | 0.972-1.056 | 0.534 |
*indicates unadjusted analysis.
Sensitivity analysis of healing rates
| -0.156 (0.087) | 0.050 (0.094) | 1.051 (0.874-1.263) | 0.5916 | |
| -0.106 (0.030) | ||||
| N/A | -0.070 (0.047) | 0.932 (0.850-1.022) | 0.1363 |
Hazard ratios, time to healing
| 1.48 (0.79,2.78) | 0.22 | |
| 0.65 (0.51,0.83) | 0.00045 | |
| 0.76 (0.43,1.36) | 0.36 | |
| 1.54 (0.90,2.64) | 0.12 | |
| 0.68 (0.31,1.49) | 0.34 | |
| 1.55 (0.41,5.85) | 0.52 |
CCI = Charlson Co-morbidity Index.
CVA = Cerebrovascular accident.
Time to healing by wound stage
| 1.02 (0.40,2.63) | 0.96 | |
| 2.16 (0.87,5.34) | 0.096 | |
| 1.58 (0.20,12.67) | 0.66 | |
| 1.00 (0.24,4.17) | 1.0 |
Exponentiated random effects for the intervention covariate
| 1 | 0.94 |
| 2 | 0.48 |
| 3 | 1.62 |
| 4 | 1.94 |
| 5 | 0.93 |
| 6 | 2.20 |
| 7 | 2.29 |
| 8 | 0.49 |
| 9 | 0.64 |
| 10 | 0.92 |
| 11 | 0.68 |
| 12 | 0.76 |
Comparison of direct care costs incurred until healing
| | |||
| Study nurse | N/A | $101 | $101 |
| MDT | N/A | $20 | $20 |
| ET | $357 | $18 | -$340 |
| Facility nurse | $1,094 | $1,486 | $392 |
| | |||
| Antibiotics | $84 | $38 | -$46 |
| Dressings | $1,623 | $2,284 | $661 |
| NPWT | $3,142 | $0 | -$3,142 |
| | |||
| Inpatient | $4,147 | $5,792 | $1,645 |
| Ambulatory (ER) | $250 | $310 | $60 |